Hyperglycemia is a key pathogenic mechanism in the initiation and progression of diabetic kidney disease (DKD), via activation of hemodynamic and nonhemodynamic factors. In experimental models of diabetes, hyperglycemia augments the production of reactive oxygen species (ROS), leading to intrarenal renin-angiotensin system (RAS) activation. RAS activation in turn promotes increased intraglomerular pressure, hypertension, and activation of proinflammatory and profibrotic mediators of kidney injury. Of particular importance for the current study by Woods et al. [1] is the previous observation by Chan and colleagues [2] that hyperglycemia increases intrarenal angiotensinogen production at the proximal tubule via nuclear proteins such heterogeneous nuclear ribonucleoprotein (hnRNP) F and hnRNP K [2] . As a consequence of ambient hyperglycemia, intrarenal RAS activation is observed in animals and humans, even though systemic, circulating levels of RAS hormones can be markedly suppressed. This phenomenon has been called the "paradox of the low renin state in diabetes," whereby intrarenal RAS activation is characteristic of diabetes in the setting of suppressed circulating levels. In animals, targeted inhibition of hnRNP F and hnRNP K, or overexpression of catalase to attenuate ROS production, blocks hyperglycemia-mediated RAS activation and angiotensinogen production [2] . As a consequence of the deleterious effect of RAS activation on cardiorenal disease, in clinical practice, angiotensin-converting enzyme (ACE) inhibitors and angiotensin II type 1 receptor (ARB) blockers are the standard of care to reduce blood pressure and slow DKD progression in patients with type 1 diabetes (T1D) and type 2 diabetes (T2D). Unfortunately, despite the use of RAS inhibitors, patients with diabetes still have a high risk of end-stage kidney disease, highlighting the need to identify novel therapies to protect against this condition.
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More recent insights into the management of DKD have been made with glucose-lowering therapies called sodium-glucose cotransporter-2 (SGLT2) inhibitors. By blocking the entry of glucose into proximal tubular cells, these agents induce a negative caloric balance leading to weight loss and HbA1c reduction -which is the current primary rationale for the use of these therapies. However, based on the mechanism of action, SGLT2 inhibitors also induce a natriuresis, resulting in plasma volume contraction and reduced glomerular pressure, as described elsewhere. More controversial, however, is the observation that SGLT2 inhibitors modulate RAS activation. This concept is of significant mechanistic and clinical importance, since SGLT2 inhibitors reduce renal hemodynamic injury and fibrosis through incompletely understood pathways that may involve the RAS-related mechanisms.
Accordingly, in the current issue of the American Journal of Nephrology, Woods et al. [1] examined the impact of the SGLT2 inhibitor canagliflozin on DKD progression in a mouse model of T2D. In their studies, SGLT2 inhibition yielded expected reductions in blood pressure -observations that have been made previously in animal models of diabetes, as well as in patients with T1D and T2D. From a mechanistic perspective, SGLT2 inhibition attenuated expected increases in renal angiotensinogen mRNA expression and protein levels in response to hyperglycemia but did not affect hepatic, adipose tissue, or plasma levels of angiotensinogen. SGLT2 inhibition also reduced levels of urinary 8-isoprostane, as a marker of oxidative stress. Beyond these functional observations, SGLT2 inhibition had a significant impact on structural measures of DKD, as reflected by suppression of tubular fibrosis and renal inflammatory markers. The overall sequence of events leading to renal protection may, in this series of studies, indicate that the hyperglycemia-ROS-RAS sequence of injury can be inhibited by blocking the entry to glucose in renal tubular cells.
Given the benefits of SGLT2 inhibitors in cardiorenal outcomes in previous cardiovascular outcome trials such as EMPA-REG OUTCOME, CANVAS Program, and DECLARE TIMI-58, it is important to understand the responsible mechanisms to optimally use these therapies in clinical care, including their use in novel settings such as in patients with non-diabetic kidney disease. SGLT2 inhibition exerts renal hemodynamic effects leading to reduced renal hyperfiltration. These hemodynamic effects are thought to occur through inducing a proximal natriuresis. Increased sodium delivery to the macula densa activates tubuloglomerular feedback through breakdown of adenosine triphosphate to adenosine, which binds to the adenosine-1 receptor, leading to afferent arteriolar vasoconstriction [3] . The increase in afferent vasoconstriction reduces renal blood flow and intraglomerular pressure, which reduces hyperfiltration and induces a modest, acute "dip" in eGFR in clinical trials. In addition, SGLT2 inhibitors may be protective through improving renal oxygenation and by lowering blood pressure and glycemic burden and by suppressing proinflammatory and profibrotic pathways directly via non-RAS mediators. The work by Woods et al. [1] is therefore important since it provides potential insights into how SGLT2 inhibitors act in kidney tissue resulting in attenuated DKD progression.
In addition to protective effects in the kidney as reflected by reduced histological evidence of DKD, Woods et al. [1] suggest a link between intrarenal RAS inhibition and blood pressure lowering. Previous work has implicated a variety of mechanisms leading to blood pressure lowering, including decreases in arterial stiffness, plasma volume, body weight, glycemic control, uric acid, and proinflammatory factors. In their experiments, as the authors point out, antihypertensive effects took more than 2 weeks to achieve, suggesting that in this animal model, blood pressure lowering was unlikely related to natriuresis/diuresis, since urine sodium loss occurs immediately after initiation of these therapies. Since blood pressure lowering occurs rapidly in humans, the observation that blood pressure declined slowly in the work by Woods et al. [1] suggests that the pattern of systemic hemodynamic change is different in animal models compared to humans.
Previous studies have examined the relationship between SGLT2 inhibition and angiotensinogen levels. As indicated by the authors, SGLT2 inhibitors have neutral or even stimulatory effects on urinary angiotensinogen in other animal models of diabetes [4] despite reducing renal histological injury across multiple experimental studies [5] . Similarly, in an animal model of nondiabetic chronic kidney disease, SGLT2 inhibition did not activate the systemic or intrarenal RAS [6] . In human studies, including patients with T1D or T2D, circulating and urine RAS mediators generally increase [7] . Since blood pressure lowering is consistent across animal and human studies [8] , despite inconsistent changes in levels of angiotensinogen and other RAS markers, it is likely that other factors cause blood pressure lowering and renal protection with SGLT2 inhibitors. From a more empirical perspective, in cardiovascular outcome trials, SGLT2 inhibitors reduce renal and cardiovascular risk regardless of background RAS inhibitor use, emphasizing that clinical benefits of SGLT2 inhibitors are independent of baseline RAS activation in humans. Despite significant insights into SGLT2 inhibitor-RAS interactions, the study by Woods et al. [1] has some important limitations. First, while renal angiotensinogen did decrease in response to canagliflozin, this does not necessarily mean that blockade of glucose entry into proximal tubular cells and a subsequent reduction in ROS generation was responsible for this effect. The impact on renal angiotensinogen may instead have been mediated by changes in distal sodium delivery, changes in levels of proinflammatory pathways, or alterations in other neurohormones, including circulating angiotensin II. Second, suppression of renal angiotensinogen levels does not elucidate the role of alternate RAS pathways including ACE-2/Angiotensin (1-7), which could also be associated with renal protection. Third, from a clinical perspective, it is important to recognize that many of the observations in this experimental study do not necessarily translate to human disease. For example, the lack of effect of canagliflozin on albuminuria is inconsistent with adequately sized human studies demonstrating 40-50% declines in albuminuria in patients with diabetes, perhaps related to decreased blood pressure and lowered intraglomerular pressure. In this regard, measures of kidney function, including hyperfiltration, were not included in this study. Accordingly, it is not possible to assess functional aspects of reductions in renal angiotensinogen on intrarenal hemodynamic mechanisms leading to kidney disease progression. Finally, it is important to recognize that the study does not mirror conventional clinical practice, since most patients on SGLT2 inhibitors, especially those with kidney disease, are also treated with an ACE inhibitor or ARB, as well as other glucose lowering agents. Consequently, further mechanistic studies are needed to determine if there are synergies with respect to renal angiotensinogen lowering and benefits on renal measures with these combined strategies.
In summary, SGLT2 inhibition is associated with a reduction in renal angiotensinogen in an animal model of T2D, as well as reductions in blood pressure and markers of renal injury. Intrarenal RAS suppression may be involved in renal protection effects with SGLT2 inhibitors. Further work is required to determine the clinical role of RAS suppression in response to SGLT2 inhibition in the setting of human disease.
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